BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26453163)

  • 1. Nanotechnology-enabled delivery of NQO1 bioactivatable drugs.
    Ma X; Moore ZR; Huang G; Huang X; Boothman DA; Gao J
    J Drug Target; 2015; 23(7-8):672-80. PubMed ID: 26453163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy.
    Ma X; Huang X; Moore Z; Huang G; Kilgore JA; Wang Y; Hammer S; Williams NS; Boothman DA; Gao J
    J Control Release; 2015 Feb; 200():201-11. PubMed ID: 25542645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albumin binding revitalizes NQO1 bioactivatable drugs as novel therapeutics for pancreatic cancer.
    Dou L; Liu H; Wang K; Liu J; Liu L; Ye J; Wang R; Deng H; Qian F
    J Control Release; 2022 Sep; 349():876-889. PubMed ID: 35907592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prodrug strategy to achieve lyophilizable, high drug loading micelle formulations through diester derivatives of β-Lapachone.
    Ma X; Huang X; Huang G; Li L; Wang Y; Luo X; Boothman DA; Gao J
    Adv Healthc Mater; 2014 Aug; 3(8):1210-6. PubMed ID: 24532286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells.
    Blanco E; Bey EA; Dong Y; Weinberg BD; Sutton DM; Boothman DA; Gao J
    J Control Release; 2007 Oct; 122(3):365-74. PubMed ID: 17574288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.
    Reinicke KE; Bey EA; Bentle MS; Pink JJ; Ingalls ST; Hoppel CL; Misico RI; Arzac GM; Burton G; Bornmann WG; Sutton D; Gao J; Boothman DA
    Clin Cancer Res; 2005 Apr; 11(8):3055-64. PubMed ID: 15837761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy as Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy.
    Zhang L; Chen Z; Yang K; Liu C; Gao J; Qian F
    Mol Pharm; 2015 Nov; 12(11):3999-4010. PubMed ID: 26415823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.
    Silvers MA; Deja S; Singh N; Egnatchik RA; Sudderth J; Luo X; Beg MS; Burgess SC; DeBerardinis RJ; Boothman DA; Merritt ME
    J Biol Chem; 2017 Nov; 292(44):18203-18216. PubMed ID: 28916726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.
    Blanco E; Bey EA; Khemtong C; Yang SG; Setti-Guthi J; Chen H; Kessinger CW; Carnevale KA; Bornmann WG; Boothman DA; Gao J
    Cancer Res; 2010 May; 70(10):3896-904. PubMed ID: 20460521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Carbon-Carbon Bond Cleavage-Based Prodrug Activation Strategy Applied to β-Lapachone for Cancer-Specific Targeting.
    Gong Q; Li X; Li T; Wu X; Hu J; Yang F; Zhang X
    Angew Chem Int Ed Engl; 2022 Oct; 61(40):e202210001. PubMed ID: 35938884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tailored Beta-Lapachone Nanomedicines for Cancer-Specific Therapy.
    Li Y; Feng M; Guo T; Wang Z; Zhao Y
    Adv Healthc Mater; 2023 Aug; 12(20):e2300349. PubMed ID: 36970948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.
    Li LS; Bey EA; Dong Y; Meng J; Patra B; Yan J; Xie XJ; Brekken RA; Barnett CC; Bornmann WG; Gao J; Boothman DA
    Clin Cancer Res; 2011 Jan; 17(2):275-85. PubMed ID: 21224367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-Lapachone Induces NAD(P)H:Quinone Oxidoreductase-1- and Oxidative Stress-Dependent Heat Shock Protein 90 Cleavage and Inhibits Tumor Growth and Angiogenesis.
    Wu Y; Wang X; Chang S; Lu W; Liu M; Pang X
    J Pharmacol Exp Ther; 2016 Jun; 357(3):466-75. PubMed ID: 27048660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-cancer effect of bio-reductive drug beta-lapachon is enhanced by activating NQO1 with heat shock.
    Song CW; Chae JJ; Choi EK; Hwang TS; Kim C; Lim BU; Park HJ
    Int J Hyperthermia; 2008 Mar; 24(2):161-9. PubMed ID: 18283592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.
    Cao L; Li LS; Spruell C; Xiao L; Chakrabarti G; Bey EA; Reinicke KE; Srougi MC; Moore Z; Dong Y; Vo P; Kabbani W; Yang CR; Wang X; Fattah F; Morales JC; Motea EA; Bornmann WG; Yordy JS; Boothman DA
    Antioxid Redox Signal; 2014 Jul; 21(2):237-50. PubMed ID: 24512128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent.
    Li JZ; Ke Y; Misra HP; Trush MA; Li YR; Zhu H; Jia Z
    Toxicol Appl Pharmacol; 2014 Dec; 281(3):285-93. PubMed ID: 25448047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer.
    Li LS; Reddy S; Lin ZH; Liu S; Park H; Chun SG; Bornmann WG; Thibodeaux J; Yan J; Chakrabarti G; Xie XJ; Sumer BD; Boothman DA; Yordy JS
    Mol Cancer Ther; 2016 Jul; 15(7):1757-67. PubMed ID: 27196777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PCNA inhibition enhances the cytotoxicity of β-lapachone in NQO1-Positive cancer cells by augmentation of oxidative stress-induced DNA damage.
    Su X; Wang J; Jiang L; Chen Y; Lu T; Mendonca MS; Huang X
    Cancer Lett; 2021 Oct; 519():304-314. PubMed ID: 34329742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of various formulation approaches for the application of beta-lapachone in prostate cancer therapy.
    Wu X; Kasselouri A; Vergnaud-Gauduchon J; Rosilio V
    Int J Pharm; 2020 Apr; 579():119168. PubMed ID: 32087264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers.
    Motea EA; Huang X; Singh N; Kilgore JA; Williams NS; Xie XJ; Gerber DE; Beg MS; Bey EA; Boothman DA
    Clin Cancer Res; 2019 Apr; 25(8):2601-2609. PubMed ID: 30617135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.